| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Natural Killer T-Cells | 20 | 2025 | 84 | 7.700 |
Why?
|
| Neuroblastoma | 25 | 2025 | 550 | 4.590 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2025 | 894 | 2.190 |
Why?
|
| Cytotoxicity, Immunologic | 12 | 2024 | 275 | 1.670 |
Why?
|
| Interleukin-15 | 7 | 2025 | 96 | 1.480 |
Why?
|
| Lymphocyte Activation | 13 | 2024 | 723 | 1.470 |
Why?
|
| Antigens, CD1d | 9 | 2024 | 21 | 1.340 |
Why?
|
| Killer Cells, Natural | 9 | 2023 | 356 | 1.220 |
Why?
|
| Gangliosides | 5 | 2025 | 73 | 1.090 |
Why?
|
| Receptors, Antigen, T-Cell | 10 | 2023 | 503 | 1.010 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2025 | 10 | 0.940 |
Why?
|
| Neoplasms | 6 | 2024 | 3037 | 0.880 |
Why?
|
| Immunologic Memory | 1 | 2025 | 199 | 0.840 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 16 | 0.820 |
Why?
|
| Cancer Vaccines | 5 | 2019 | 190 | 0.780 |
Why?
|
| Immunotherapy | 5 | 2019 | 752 | 0.770 |
Why?
|
| Lymphoma, B-Cell | 3 | 2018 | 149 | 0.750 |
Why?
|
| Mice, SCID | 10 | 2023 | 615 | 0.730 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2025 | 1012 | 0.700 |
Why?
|
| Interleukins | 2 | 2020 | 130 | 0.700 |
Why?
|
| Mice | 32 | 2025 | 19047 | 0.680 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 703 | 0.680 |
Why?
|
| L-Selectin | 2 | 2018 | 22 | 0.660 |
Why?
|
| Galactosylceramides | 6 | 2018 | 15 | 0.650 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2016 | 214 | 0.640 |
Why?
|
| Mice, Inbred NOD | 9 | 2023 | 318 | 0.640 |
Why?
|
| Th1 Cells | 2 | 2018 | 159 | 0.610 |
Why?
|
| Receptors, Antigen | 2 | 2016 | 34 | 0.570 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3796 | 0.570 |
Why?
|
| T-Lymphocytes | 10 | 2024 | 1812 | 0.560 |
Why?
|
| Macrophages | 6 | 2024 | 711 | 0.550 |
Why?
|
| Animals | 34 | 2025 | 36545 | 0.540 |
Why?
|
| Glypicans | 3 | 2024 | 41 | 0.510 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 447 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 1187 | 0.440 |
Why?
|
| Antigens, CD1 | 3 | 2003 | 23 | 0.400 |
Why?
|
| Humans | 48 | 2025 | 134084 | 0.370 |
Why?
|
| Medulloblastoma | 2 | 2013 | 571 | 0.350 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 698 | 0.340 |
Why?
|
| Cell Proliferation | 7 | 2020 | 2562 | 0.320 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 521 | 0.320 |
Why?
|
| Interleukin-2 | 2 | 2018 | 252 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 7 | 2020 | 1107 | 0.310 |
Why?
|
| Antigen-Presenting Cells | 3 | 2019 | 133 | 0.290 |
Why?
|
| Cells, Cultured | 7 | 2018 | 3187 | 0.290 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2007 | 247 | 0.290 |
Why?
|
| Oncogene Proteins | 2 | 2012 | 157 | 0.280 |
Why?
|
| Chemokine CCL2 | 2 | 2007 | 134 | 0.280 |
Why?
|
| Cytokines | 7 | 2016 | 1400 | 0.280 |
Why?
|
| STAT3 Transcription Factor | 5 | 2015 | 231 | 0.280 |
Why?
|
| Cell Movement | 3 | 2012 | 920 | 0.270 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 746 | 0.250 |
Why?
|
| Flow Cytometry | 3 | 2010 | 837 | 0.250 |
Why?
|
| CD28 Antigens | 2 | 2016 | 81 | 0.240 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 181 | 0.220 |
Why?
|
| Apoptosis | 8 | 2020 | 1946 | 0.220 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 399 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 3 | 2019 | 392 | 0.210 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2003 | 7 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 137 | 0.210 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2023 | 15 | 0.200 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2023 | 36 | 0.200 |
Why?
|
| Etanercept | 1 | 2023 | 47 | 0.200 |
Why?
|
| Granzymes | 2 | 2018 | 48 | 0.200 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 22 | 0.200 |
Why?
|
| Macrophage-1 Antigen | 1 | 2002 | 33 | 0.190 |
Why?
|
| Protein Domains | 1 | 2023 | 260 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 825 | 0.190 |
Why?
|
| Interleukin-7 | 2 | 2017 | 50 | 0.190 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 296 | 0.190 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 1347 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 506 | 0.190 |
Why?
|
| Receptors, IgG | 1 | 2002 | 64 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2019 | 806 | 0.190 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 224 | 0.180 |
Why?
|
| Interleukin-6 | 3 | 2024 | 451 | 0.180 |
Why?
|
| beta Catenin | 1 | 2023 | 232 | 0.180 |
Why?
|
| Monocytes | 1 | 2023 | 360 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2018 | 61 | 0.170 |
Why?
|
| Antibodies | 1 | 2002 | 382 | 0.170 |
Why?
|
| Vidarabine | 1 | 2020 | 78 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 825 | 0.170 |
Why?
|
| Homeostasis | 1 | 2004 | 751 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2023 | 364 | 0.160 |
Why?
|
| Transduction, Genetic | 3 | 2019 | 296 | 0.160 |
Why?
|
| Neutrophils | 1 | 2002 | 402 | 0.160 |
Why?
|
| Immunity | 1 | 2020 | 186 | 0.160 |
Why?
|
| CD3 Complex | 1 | 2019 | 93 | 0.160 |
Why?
|
| Antigens, Neoplasm | 3 | 2019 | 407 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 294 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 51 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 426 | 0.150 |
Why?
|
| Bone Marrow | 3 | 2007 | 336 | 0.150 |
Why?
|
| Hypoxia | 2 | 2016 | 268 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2021 | 290 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2015 | 94 | 0.140 |
Why?
|
| Contrast Media | 1 | 2021 | 518 | 0.140 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 2 | 2015 | 10 | 0.130 |
Why?
|
| Salmonella typhimurium | 2 | 2014 | 43 | 0.130 |
Why?
|
| Child | 6 | 2023 | 25870 | 0.130 |
Why?
|
| Vaccines, Attenuated | 2 | 2014 | 176 | 0.130 |
Why?
|
| Cell Survival | 2 | 2016 | 890 | 0.130 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 26 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 1072 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 105 | 0.120 |
Why?
|
| Melanoma | 2 | 2019 | 967 | 0.120 |
Why?
|
| Glycolysis | 1 | 2016 | 173 | 0.120 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2013 | 65 | 0.120 |
Why?
|
| Glioblastoma | 2 | 2017 | 375 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 2 | 2015 | 352 | 0.120 |
Why?
|
| Glycolipids | 2 | 2019 | 35 | 0.120 |
Why?
|
| Peptides | 1 | 2019 | 862 | 0.120 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 11 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2011 | 47 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2001 | 1853 | 0.110 |
Why?
|
| Retroviridae | 1 | 2014 | 198 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2013 | 2911 | 0.110 |
Why?
|
| Cell Line | 2 | 2014 | 2860 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2198 | 0.100 |
Why?
|
| Glycosphingolipids | 1 | 2012 | 11 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 787 | 0.100 |
Why?
|
| Salmonella enterica | 1 | 2012 | 9 | 0.100 |
Why?
|
| Antigens | 1 | 2012 | 157 | 0.090 |
Why?
|
| Immunophenotyping | 2 | 2003 | 342 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2011 | 18 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2011 | 63 | 0.090 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 38 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2012 | 119 | 0.090 |
Why?
|
| Models, Immunological | 1 | 2010 | 38 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 1007 | 0.090 |
Why?
|
| Salmonella | 1 | 2010 | 29 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 232 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2017 | 4934 | 0.080 |
Why?
|
| Virulence Factors | 1 | 2012 | 187 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 645 | 0.080 |
Why?
|
| Ceramides | 2 | 2000 | 47 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 619 | 0.080 |
Why?
|
| Vaccination | 2 | 2012 | 1017 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1417 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2011 | 872 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 721 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 259 | 0.070 |
Why?
|
| Ligands | 2 | 2019 | 572 | 0.070 |
Why?
|
| Male | 7 | 2024 | 66093 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 4878 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2016 | 4015 | 0.070 |
Why?
|
| Female | 12 | 2024 | 71893 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 2137 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2011 | 544 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 275 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 2011 | 461 | 0.070 |
Why?
|
| CD56 Antigen | 2 | 2003 | 29 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1317 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1071 | 0.060 |
Why?
|
| RNA Interference | 1 | 2007 | 548 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 67 | 0.060 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2024 | 15 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 103 | 0.060 |
Why?
|
| Thymus Gland | 1 | 2004 | 106 | 0.060 |
Why?
|
| Genes, myc | 1 | 2004 | 107 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1331 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 146 | 0.050 |
Why?
|
| Phenotype | 3 | 2013 | 4570 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2013 | 14867 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 19 | 0.050 |
Why?
|
| Perforin | 1 | 2003 | 26 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 672 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 1433 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2024 | 122 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 434 | 0.050 |
Why?
|
| Protein Binding | 1 | 2007 | 1858 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 1440 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2002 | 538 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 204 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 69 | 0.050 |
Why?
|
| Exocytosis | 1 | 2002 | 66 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2539 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 23 | 0.050 |
Why?
|
| Immunomagnetic Separation | 1 | 2001 | 12 | 0.050 |
Why?
|
| Cytoplasmic Granules | 1 | 2002 | 52 | 0.050 |
Why?
|
| U937 Cells | 1 | 2001 | 25 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2001 | 35 | 0.050 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2001 | 11 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2001 | 95 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 50 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 79 | 0.040 |
Why?
|
| Radiometry | 1 | 2021 | 42 | 0.040 |
Why?
|
| Brain Neoplasms | 3 | 2010 | 1409 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 433 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2012 | 44 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 358 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1627 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 259 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 2000 | 4 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2011 | 145 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 1391 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 94 | 0.040 |
Why?
|
| Fenretinide | 1 | 1999 | 10 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2001 | 838 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 3178 | 0.040 |
Why?
|
| Integrins | 1 | 2000 | 103 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 1096 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1999 | 57 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2015 | 2044 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 19 | 0.040 |
Why?
|
| Infant | 3 | 2012 | 13230 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 20610 | 0.040 |
Why?
|
| K562 Cells | 1 | 2019 | 100 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 74 | 0.040 |
Why?
|
| Adult | 4 | 2022 | 31930 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 1999 | 87 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1761 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 1089 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 138 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2669 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2014 | 13074 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1999 | 117 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2000 | 220 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 125 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 69 | 0.030 |
Why?
|
| Machine Learning | 1 | 2021 | 339 | 0.030 |
Why?
|
| Epitopes | 1 | 2019 | 446 | 0.030 |
Why?
|
| Genome, Human | 1 | 2004 | 1345 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 522 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2014 | 452 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1356 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1999 | 535 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2003 | 1923 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2016 | 127 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3667 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 183 | 0.030 |
Why?
|
| Dendritic Cells | 2 | 2010 | 449 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5217 | 0.030 |
Why?
|
| Side-Population Cells | 1 | 2013 | 12 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 780 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2013 | 797 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 8 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2012 | 25 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5477 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1721 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 38 | 0.020 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2012 | 119 | 0.020 |
Why?
|
| Salmonella Vaccines | 1 | 2012 | 7 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 907 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 2012 | 30 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2012 | 247 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2012 | 321 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 276 | 0.020 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 16 | 0.020 |
Why?
|
| Codon | 1 | 2011 | 109 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 337 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 204 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 1787 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2012 | 177 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 390 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 322 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 289 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 451 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 2010 | 32 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 972 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 497 | 0.020 |
Why?
|
| Virulence | 1 | 2010 | 279 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 624 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 69 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2009 | 23 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 934 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 839 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 272 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 970 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 313 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1613 | 0.020 |
Why?
|
| Glycosylation | 1 | 2006 | 128 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1137 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 951 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 2266 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2006 | 320 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 1594 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 29394 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17538 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 2175 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2002 | 6 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 74 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 5086 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 148 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2002 | 120 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2002 | 100 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 2001 | 19 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 2001 | 34 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2001 | 61 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 993 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2000 | 38 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 93 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1999 | 11 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 1999 | 35 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 61 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 3223 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 221 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2002 | 8617 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 650 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1999 | 261 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 320 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 3979 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2172 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1765 | 0.010 |
Why?
|